touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.
- Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26)
- What was the rationale for investigating avapritinib in the treatment of patients with advanced systemic mastocytosis? (1:04)
- Could you tell us a little about the PATHFINDER study and its findings? (1:39)
- How clinically meaningful are these benefits? (2:35)
Disclosures: In relation to this video interview, MM has received honoraria for advice as well as institutional research support by Blueprint and Celldex.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 EAACI Annual Meeting.
Share this Video
Related Videos In Dermatological Conditions
Christian Vestergaard, EADV 2021: Biologics for Paediatric Skin Diseases
It was a pleasure to meet Dr Christian Vestergaard (Aarhus University Hospital, Aarhus, Denmark) to discuss the use of biologics in the treatment of paediatric skin diseases. His presentation entitled ‘The use of biological drugs for skin diseases in children’ was presented at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions What […]
Rosalie Luiten, EADV 2021: The Role of Resident Memory T-cells in Vitiligo and Tumour Immunity
touchIMMUNOLOGY were delighted to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the role of resident memory T cells in autoimmune vitiligo and tumour immunity, and how they could be used as a therapeutic target. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the […]
Rosalie Luiten, EADV 2021: The Link between Vitiligo and Melanoma
It was a pleasure to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the immunological link between vitiligo and melanoma. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Questions How are vitiligo and melanoma linked? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!